SCHEMBL5879271

SCHEMBL5879271

O=c1[nH]c(=O)c2c1c1[nH]c3c(OCc4ccccc4)cccc3c1c1c(=O)[nH]c(=O)c21

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 1/20 0.53
PIK3CG P48736 1/20 0.48
CHEK1 O14757 2/20 0.48
LTA4H P09960 1/20 0.45
PLA2G2A P14555 1/20 0.45
TRPM8 Q7Z2W7 1/20 0.45
SRD5A2 P31213 1/20 0.43
MAPT P10636 1/20 0.43
MAPK1 P28482 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MAOB P27338 1/20 0.42
LMNA P02545 1/20 0.41
CTSV O60911 2/20 0.40
CTSL P07711 2/20 0.40
LOXL2 Q9Y4K0 1/20 0.40
MGLL Q99685 1/20 0.40
MMP13 P45452 1/20 0.39
USP2 O75604 1/20 0.39
ALDH1A1 P00352 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8769400 0.80 PRKCA (0.52) ADORA3PIK3CGCHEK1LTA4HPLA2G2A
SCHEMBL5879163 0.77 KDM4E (0.55) CHEK1MAPTL3MBTL1LMNAALDH1A1
SCHEMBL5879176 0.75 CTSV (0.63) CHEK1SRD5A2CTSVCTSLALDH1A1
SCHEMBL8314297 0.74 NQO1 (0.47) ADORA3PIK3CGCHEK1LTA4HPLA2G2A
SCHEMBL27777168 0.74 SRD5A2 (0.56) ADORA3PIK3CGLTA4HPLA2G2ATRPM8
SCHEMBL5879262 0.74 CTSV (0.61) CHEK1MAOBCTSVCTSLALDH1A1
SCHEMBL5879186 0.74 MAOA (0.58) CHEK1TRPM8SRD5A2MAOBCTSV
SCHEMBL9348479 0.74 ADORA3 (0.48) ADORA3PIK3CGLTA4HPLA2G2ATRPM8
SCHEMBL20945154 0.73 MAOB (0.50) ADORA3LTA4HPLA2G2ATRPM8SRD5A2
SCHEMBL11115687 0.71 MAPT (0.60) ADORA3PIK3CGLTA4HPLA2G2ATRPM8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7151108-B2 Anticarcinogenic, antiproliferative, and antitumor agents LES LABORATORIES SERVIER (FR) 2006-12-19 US disclosed
EP-1411057-B1 [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2005-04-27 EP disclosed
US-20040077672-A1 Anticarcinogenic, antiproliferative, and antitumor agents LES LABORATOIRES SERVIER (FR) 2004-04-22 US disclosed
EP-1411057-A1 [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2004-04-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077672-A1 Anticarcinogenic, antiproliferative, and antitumor agents XDH, TOP2A, TOP1 ADORA3 2648/4885PIK3CG 4642/4885CHEK1 943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.